Bellevue Group AG Acquires 35,069 Shares of Humana Inc. (NYSE:HUM)

Bellevue Group AG raised its holdings in Humana Inc. (NYSE:HUM) by 34.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 135,541 shares of the insurance provider’s stock after buying an additional 35,069 shares during the quarter. Bellevue Group AG owned 0.11% of Humana worth $46,995,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of HUM. Rakuten Securities Inc. bought a new position in Humana during the fourth quarter worth $25,000. Gradient Investments LLC grew its stake in shares of Humana by 200.0% in the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock valued at $27,000 after buying an additional 40 shares during the period. Cetera Trust Company N.A bought a new stake in Humana in the 4th quarter valued at about $28,000. Private Wealth Management Group LLC acquired a new position in Humana during the 4th quarter worth approximately $32,000. Finally, Carolinas Wealth Consulting LLC boosted its holdings in Humana by 274.1% in the fourth quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock worth $46,000 after acquiring an additional 74 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. UBS Group cut their target price on Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, April 25th. Morgan Stanley began coverage on shares of Humana in a report on Monday, June 24th. They set an “equal weight” rating and a $374.00 price objective for the company. Oppenheimer lowered their target price on shares of Humana from $415.00 to $370.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. Jefferies Financial Group cut their price target on Humana from $411.00 to $381.00 and set a “buy” rating for the company in a research note on Monday, April 22nd. Finally, Piper Sandler started coverage on Humana in a research note on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 price objective for the company. Fourteen equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $402.60.

Humana Stock Performance

Shares of NYSE:HUM traded up $6.23 during mid-day trading on Friday, reaching $392.63. The company had a trading volume of 1,003,973 shares, compared to its average volume of 1,301,923. Humana Inc. has a one year low of $298.61 and a one year high of $530.54. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77. The company’s 50-day moving average price is $365.66 and its 200-day moving average price is $347.02. The firm has a market cap of $47.31 billion, a price-to-earnings ratio of 24.45, a PEG ratio of 2.27 and a beta of 0.51.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.12 by $1.11. The firm had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. The business’s revenue was up 10.7% on a year-over-year basis. During the same period in the previous year, the company posted $9.38 earnings per share. As a group, equities research analysts anticipate that Humana Inc. will post 16.27 EPS for the current fiscal year.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.